



Emergency Treatment of Anaphylactic Reactions

Dr John Vassiliadis Staff Specialist Emergency Medicine Deputy Director Sydney Clinical Skills and Simulation Centre, RNSH Clinical Lecturer, University of Sydney







Anaphylaxis

• Update Essentials

- Recognition
- Treatment
- Investigations
- Discharge and follow up
- Case



Introduction

- Incidence is increasing, 0.5-30 severe cases/10000 people and 1-3 deaths per million¹
- Sales of EpiPen junior increased by 300%; sales of EpiPen by 193%²
- True Emergency
 - Rapid and unpredictable onset
 - Potentially lethal
 - Effective widely available treatment
 - Patients are young and healthy
 - Transcends all medical specialties



- . 'Mounter -Vautrin DA et al. Epidemiology of pre-lethal and lethal anaphylaxis. (English). Revue Francaise d'Allergologie et d'Immunologie Clinique 2004; 44(3):315.
- · ²Kemp A. EpiPen epidemic: Suggestions for rational prescribing in childhood food allergy. Journal of Paediatrics & Child Health 2003; 39(5):372-375.

History



- Index case allegedly was Pharaoh Menes in 2640 BC who was stung by a wasp aged 3 and died of an anaphylactic reaction
- In 1902 Prince Albert | invited 2 Parisian scientists (Charles Richet & Paul Portier) aboard his yacht to study the Portuguese man of War jellyfish.
 - They isolated the toxin and tried to vaccinate dogs
 - They discovered a new illness that killed within 30 minutes mainly through breathing difficulties
 - They coined anaphylaxis (against protection)

History

In 1956, Mary Hewitt Loveless showed that injecting wasp venom could cause anaphylaxis in people allergic to wasps
She then successfully used wasp extracts to immunise these patients

Definition


- Anaphylaxis is a severe, life threatening, generalised or systemic hypersensitivity reaction¹
- Causes of anaphylaxis divided into 2 groups:
 - IgE mediated: This form is the true anaphylaxis that requires an initial sensitizing exposure, the coating of the mast cells and basophils by IgE, and the explosive release of chemical mediators upon re-exposure
 - Non-IgE mediated: These reactions, the so called "anaphylactoid" reactions, are similar to those of true anaphylaxis, but do not require an IgE immune reaction. They are usually caused by the direct stimulation of the mast cells and basophils. The same mediators as occur with true anaphylaxis are released and the same effects are produced. This reaction can happen, and often does, on initial as well as subsequent exposures, since no sensitization is required.

Actiology


Venomous stings and Bites	Ants, bees, wasps
Drugs	Penicillins, cephalosporins, cotrimoxazole, NSAIDS, narcotics, radiological contrast, ACE inhibitor, vaccines, gelofusin
Food	sea food, nut, egg, monosodium glutamate, kiwi fruit
Idiopathic	
Other	Exercise induced, latex

Brown SGA. Anaphylaxis: Clinical concepts and research priorities. Emergency Medicine Australasia (2006) 18, 155-169

Spectrum of Allergic Emergencies



Time Course for Fatal Reactions



Gupta et al. Time trends in allergic disorders in the UK. Thorax 2007; 62(1):91-6



Clinical Features of Anaphylaxis

General	Anxiety, malaise, weakness, paresthesia, dry mouth
Cutaneous	Nasal congestion, rhinorrhoea, conjuctival erythema, tearing, itch, flushing, urticaria, angioedema
GIT	Nausea, vomiting, abdominal pain, diarrhoea
Respiratory	Upper airway oedema(difficulty speaking, swallowing, hoarseness, stridor), dyspnoea, bronchospasm, hypoxaemia
CVS	Tachycardia, hypotension, arrhythmias, cardiogenic shock, pulmonary oedema, cardiac arrest
CNS	Headache, dizziness, confusion, LOC

Brown SGA. Anaphylaxis: Clinical concepts and research priorities. Emergency Medicine Australasia (2006) 18, 155-169

Recognition of Anaphylaxis

- Anaphylaxis is likely if:
 - Patient is exposed to allergen
 - Develops rapidly progressing symptoms and signs (within minutes)
 - Usually involves skin/mucosa, life threatening airway/breathing and/or circulation problems
 - Reaction is usually unexpected

Traps even for experienced players

- Diagnostic difficulty caused by:
 - Lack of consistent clinical manifestations and variability of presentation
 - Differential diagnosis (severe asthma, septic shock, vaso vagal, panic attack, idiopathic (non allergic) urticaria or angioedema
- Inappropriate use of adrenaline or lack of adrenaline for significant anaphylaxis

Severity grading

Grade	Defined By
Mild (skin and subcutaneous tissue)	Generalised erythema, urticaria, periorbital oedema or angioedema
Moderate (features suggestive of Respiratory, CVS and or GIT involvement)	Dyspnoea, stridor, wheeze, nausea, vomiting, dizziness, diaphoresis, chest or throat tightness, abdominal pain
Severe (hypoxia, hypotension or CNS involvement)	Cyanosis or $\text{SpO}_2 \le 92\%$, hypotension (SBP < 90 mmHg in adults), confusion, collapse, LOC or incontinence

Brown SGA. Anaphylaxis: Clinical concepts and research priorities. Emergency Medicine Australasia (2006) 18, 155-169

Management

- Depends on
 - Location
 - Training and skills of rescuers
 - Number of responders
 - Equipment and drugs available

Resuscitation Council UK. January 2008

Management

- As diagnosis is not always obvious, follow a systematic approach to critically ill patient
- Use ABCDE approach
- Treat life threatening problems as you find them
- Basic principles of treatment are the same for all age groups


The Basics

Recognition of ill patient
Call for help early
Assess and manage ABCDEs
Adrenaline therapy if indicated
Investigation and follow up by allergy specialist

Therapeutic Considerations

Adrenaline (β>α)	IM 0.01 mg/kg up to 0.5mg (1:10000) IV 0.3-0.5mg of 1:10000 in severe shock, 2 nd dose required in 35%, infusion in 10%
Posture	Lie Flat with legs elevated
Fluids	Bolus 20ml/kg, up to 40ml/kg total
Atropine & Vasopressors	Consider atropine for refractory bradycardia (0.02mg/kg); consider metaraminol (2-10 mg in adults) for persistent hypotention
Antihistamines	Selective non sedating agents for symptomatic relief of skin symptoms only. NO ROLE FOR IV PHENERGAN
Steroids	No proven benefit, particularly early. No harm in giving.

Brown SGA. Anaphylaxis: Clinical concepts and research priorities. Emergency Medicine Australasia (2006) 18, 155-169



Case

- 35 year old man presents for sclerotherapy of varicose veins in his right leg
 - Past history is unremarkable
 - No medications, no allergies, non smoker, 20-3g0ms of alcohol/day
 - Married, factory floor manager



10 minutes after LA and sclerosing solution is injected into his leg

What Do you Do?

- Stop any infiltration and procedure
- Get help
- Check ABCDEs
- Consider non sedating antihistamine for symptomatic relief
- Advise observation in ED
- Advise transport by ambulance
- Document, refer to immunologist
- Follow up

Case

- Same case but.....
 - Anxious
 - Paraesthesia to tongue and lips
 - Difficulty speaking
 - Chest tightness
 - Generalised rash
 - Not feeling well, nausea, dizzy




What Do You Do?





Case

- Call for help
- Callooo
- DRABCDE
- Keep patient and yourself as calm as possible
- Apply oxygen via NRBM
- Give 5ml 1:1000 nebulised adrenaline
- Give 0.3-0.5 mg adrenaline IM
- Insert |V and start |V fluids (stat)



Case

- Minimal improvement
- Paramedícs are on their way when:
 - Becomes centrally cyanosed
 - Increasing chest tightness and bronchospasm
 - Fluctuating level of consciousness, unable to measure BP
 - Vomits and aspirates



- Reassess ABC
- ALS principles
- Suction airway if possible
- Support airway
- Start CPR if not responsive



Titrate 100micrograms |V at a time of adrenaline (dilute 1 ml of 1:1000 with 10mls normal saline)

Crisis Resource Management

 Know your environment Anticipate and Plan Call for help Prioritise Allocate attention wisely Distribute workload Communicate effectively

Thank You

